SG Americas Securities’s Neurogene NGNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-3,576
Closed -$150K – 3453
2024
Q3
$150K Buy
+3,576
New +$139K ﹤0.01% 2741
2024
Q2
– Sell
-2,348
Closed -$120K – 3158
2024
Q1
$120K Buy
+2,348
New +$78.4K ﹤0.01% 2415
2021
Q4
– Sell
-1,117
Closed -$162K – 3673
2021
Q3
$162K Buy
+1,117
New +$171K ﹤0.01% 3373
2020
Q4
– Sell
-6,431
Closed -$1.54M – 3447
2020
Q3
$1.54M Buy
6,431
+5,622
+695% +$1.36M 0.01% 926
2020
Q2
$269K Buy
+809
New +$211K ﹤0.01% 2613
2017
Q1
– Sell
-394
Closed -$130K – 3498
2016
Q4
$130K Buy
+394
New +$106K ﹤0.01% 2698

Other funds holding NGNE

SG Americas Securities's NGNE Position: Q4 2024 in Review

SG Americas Securities sold out of Neurogene (NGNE) in Q4 2024, closing a stake of 3,576 shares — an estimated $150K sold.

SG Americas Securities first reported a position in NGNE in Q4 2016 and held it in 6 quarters. The position peaked at $1.54M in Q3 2020. 88 funds tracked by Wall St. Rank hold NGNE as of Q4 2024.

  • SG Americas Securities reported no remaining Neurogene position as of Q4 2024 after selling out during the quarter.
  • SG Americas Securities sold 3,576 Neurogene shares in Q4 2024, an estimated $150K.
  • SG Americas Securities first reported a position in Neurogene in Q4 2016 and held it in 6 quarters.
  • SG Americas Securities's Neurogene position peaked at $1.54M in Q3 2020.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q4 2024.

Based on SG Americas Securities's 13F filing for Q4 2024, filed 17 Jan 2025.